Drug Profile
Research programme: cancer therapeutics - Evotec SE/Storm Therapeutics
Alternative Names: METTL3 inhibitors - Evotec SE/Storm TherapeuticsLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Evotec AG; Storm Therapeutics
- Developer Evotec SE; Storm Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (PO)
- 08 Aug 2023 Updated pharmacodynamics data from a preclinical trial in Solid tumours released by Storm Therapeutics
- 28 Jan 2021 No recent reports of development identified for research development in Cancer in Germany